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\s=b\The direct and indirect costs associated with schizophre-
nia in Australia were calculated using the incidence approach
and compared with similar costings of myocardial infarction in
Australia and the United States. In Australia schizophrenia
affects one-twelfth as many people as does myocardial infarc-
tion, yet costs half as much. This is because the stream of
costs associated with each case of schizophrenia is six times
the stream of costs associated with myocardial infarction. To
illustrate the utility of this costing approach, the information
was used to estimate the cost-benefit ratio likely to follow the
introduction of social intervention strategies. The information
also showed that Australian support for research in schizo-
phrenia is inadequate when compared with that for myocardial
infarction and quite out of proportion to the cost of schizophre-
nia to the community.
(Arch Gen Psychiatry 1985;42:537-543)
There is a problem of supply and demand in health care.Although the amount of money available for health care
is limited, there is no limit to the potential amount that
could be spent if all existing demands were to be met. The
discrepancy between the demand for services and their
available supply requires that some rational means be found
for allocating scarce resources among the various sectors
demanding them. The most desirable method, from an
economic point of view, would be an allocation based on a
comparison of the costs and benefits of each policy option.
Cost comparisons of health programs require that we put
some monetary value on the morbidity and mortality associ¬
ated with various types ofdisease. The very idea of attempt¬
ing such an estimate is morally repugnant to many who
argue that "you can't measure life and suffering in monetary
terms." This argument ignores the fact that decisions and
choices in regard to health programs are already being
made. They do not disappear if we refuse to acknowledge
them; they are simply made implicitly on the basis of "same
as last year plus or minus 5% for pressure groups."1(p76) Even
those who eschew economic models are often guilty of
implicitly using them. Whenever an appeal is made for
funds on the basis of the prevalence of a particular disease, a
simple economic model of the costs of illness is presupposed,
one in which the economic importance of disease is a simple
function of its prevalence.
Schizophrenia affects some 0.5% of the population and
produces a large morbidity and a small but definite mor¬
tality. In these ways it is unlike heart disease or cancer, the
diseases most commonly costed, for they affect a much
larger portion of the community and often produce death
rather than chronic disability. In this report we will esti¬
mate the costs of schizophrenia in the state of New South
Wales, Australia. New South Wales (NSW) is the largest
state in Australia, with a largely urban population of some 5
million people. We will then compare these costs with the
costs ofmyocardial infarction in NSW measured in the same
manner and with the costs of myocardial infarction in the
United States again costed in the same manner. In the
interests of uniformity all costs in this article are expressed
in 1975 US dollars. We acknowledge that intercountry and
even interstate variations in direct costs will be large and
related both to the cost of living and the prevailing system
for financing medical care. However, if psychiatry is to
obtain a proper share of the health budget, we must produce
data that are of use to health planners.
METHODS
Concepts Used In Costing Illness
Direct costs are those associated with medical care expenditures
for diagnosis and treatment. They include hospital costs, outpa¬
tient costs, nursing care, drugs, services of professionals, and
rehabilitation costs. The indirect costs of illness are usually
confined to the earnings that are forgone on account of illness. This
is derived from the "human capital approach" to valuing life in
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which healthy human beings are regarded as a productive labor
resource.
There are two principal approaches to costing disease. In the
prevalence approach, disease costs and productivity losses are
assigned to the years in which they occur. It provides an answer to
the question: What did all cases of disease  cost in year y, directly
because of treatment costs and indirectly because of lost productiv¬
ity? The incidence approach "is based on the principle that the
stream of costs associated with an illness should be assigned to the
year in which the stream begins ."2(pl7) All future direct and indirect
costs are "present-valued," ie, measured in the dollars of the year
in which the illness first occurs. The incidence approach provides
an answer to the question: What will new cases of disease  
occurring in year y cost directly and indirectly in the long term
when valued in year y dollars?
The approach to costing that is ultimately chosen will depend on
the purpose. If cost control is the aim of the exercise, then
prevalence-based costing will suffice. It identifies the major
contributors to current expenditure and identifies possible targets
for economy. If the aim of the exercise is to make decisions about
which treatment or research strategy to implement, then the
incidence-based approach is the most appropriate, for it provides
predictions about the likely savings from programs that reduce
incidence or improve outcome. How are prevalence- and incidence-
based approaches related? In general, prevalence estimates are
larger than incidence estimates. The discrepancy between the two
increases as the discount rate (a measure of the effect of inflation on
the value of money) increases, as the duration of the disease
increases, and as annual treatment costs increase over the course
of the disease.
The incidence-based method of Hartunian et al2 was carefully
followed in the present study. Direct costs were estimated by
summing all treatment-related costs for each age and sex for each
year of the illness over the expected life span of the affected
individuals. This required information about age, sex, and disease-
specific incidence, survival probability, and treatment costs, to¬
gether with an assumption about the discount rate. Indirect costs
were measured from the forgone earnings that have been "dis¬
counted back to the year of incidence."2(p4Z> Housework was valued
by means of the "market value of services performed." Forgone
productivity may occur because of death or permanent or tempo¬
rary disability. Each was separately estimated and the threequantities multiplied by the appropriate incidence before being
summed to give total indirect costs. The model of Hartunian et al
assumes two things: the affected person would have lived the
expected life span for someone of his or her sex and age, if he or she
had not become ill, and he or she would have earned the same
amount as his or her age peers during this period. In this way
future earnings forgone because of death or permanent or tempo¬
rary disability were estimated by subtracting from the expected
earnings of a well peer the expected future earnings of a person
with the disease under study. Social security payments or invalid
pensions, which are regarded as transfer payments by the model,
are not included.
Incidence-based costing requires a detailed knowledge of the
epidemiology and natural history of disease as well as detailed
demographic data on life expectancy, employment rates, and
average earnings of the normal, nondiseased population. Data not
available may have to be estimated, and even the data that are
available may be varyingly trustworthy. Hartunian et al2 dealt with
this problem by investigating the sensitivity ofcosting estimates to
variations in the parameters entering into the equations. It
involves varying the values of key parameters through the likely
range of their values and tabulating the effects on total estimates.
The outcome is an estimate of the imprecision of the costing and is
analogous to a confidence interval for the estimated total cost. The
results of the sensitivity analysis of the present study are pub¬
lished elsewhere.3
Sources of Data
From 1964 to 1977 the State Department of Health and the
Australian Bureau of Statistics collaborated on a register of
inpatients in psychiatric centers.4 These centers included all state
psychiatric institutions, all authorized private psychiatric hospi-
tais, and all the psychiatric units of general hospitals. In NSW a
proportion of psychiatric patients were also admitted to private
hospitals registered as medical rather than psychiatric. We have
obtained information about the number of psychiatric patients in
these "unauthorized" hospitals and conclude that the register
covered 89% of psychiatric admissions. The number of new cases on
the register was adjusted to allow for this failure in ascertainment.5
All authorized psychiatric centers supplied the name, address,
date of birth, sex, dates of admission and discharge, and diagnosis
in accord with the International Classification ofDiseases, eighth
revision. All persons were given a unique identifier that allowed
name changes through marriage or alias to be identified. Periods of
leave of less than 12 days were not taken as evidence of discharge.
Readmission to the same or another hospital within 12 days of
discharge was counted as one admission period. Computerized
linkage analysis allowed admissions to different hospitals for the
same acute exacerbation to be identified as a single admission.
The present investigation was confined to the years 1974-1975,
1975-1976, and 1976-1977 when 4,852, 5,045, and 4,780 admissions
for schizophrenia were recorded from a population base of
4,914,277 persons resident in NSW in 1976." The boundaries of the
state make it unlikely that there would be a net outflow or inflow of
psychiatric patients from the adjoining states, so that the cost
estimates can be taken as representative of this state at that time.
Tables of first admissions for schizophrenia by age and sex during
the three years were obtained and the average of these data was
used for the calculations.
The ratio of total to first admissions was used to estimate the
expected number of admissions during the course of the illness.
Between 1974 and 1977 the ratio of total to first admissions was
4.52:1. Thus, on average, a patient had one first and 3.52 follow-up
admissions. To calculate the overall yearly admission rate for
subsequent admissions we divided the total expected years of
survival for all patients by the total number of patients to derive
the average life expectancy after diagnosis. This was 37.22 years
for men and 38.62 years for women. This figure was divided into
3.52 (the average number of follow-up admissions) to give the
overall yearly readmission rate, 0.095 for men and 0.091 for women.
In the studies of Hartunian et al in the United States2 and in the
NSW Heart Disease Study,6 which will be used as comparisons, the
age-specific likelihood of recurrence was assumed to be constant
over the expected life of the individual. In the case of schizophre¬
nia, recurrent admissions are more likely early than late in the
course of the illness. As the assumption of a constant likelihood of
readmission errs in the conservative direction, in the interests of
uniformity it was retained in the main analysis in this study.
The extent of the underestimate that derives from the assump¬
tion of a constant recurrence rate depends on the discount factor
used. A discount rate has to be included because a dollar spent now
is more valuable than a dollar spent in the future. In the interests of
uniformity with the other studies, the conservative discount rate of
6% was chosen.
The mean length of stay for all patients with a diagnosis of
schizophrenia in all hospitals is available in the NSW hospital
morbidity reports.7 In 1978, 1979, and 1980, the period of peak
admission of the three-year cohort being studied, these figures
were 146.7, 147.4, and 134.5 days, respectively. A separate source
of length-of-stay information was the register of inpatients4 that
provided the period spent in the hospital by patients with schizo¬
phrenia in the year from July 1976 to June 1977. The maximumpossible length of stay was 365 days, so skewing of the figures by a
relatively small number of more or less permanently institu¬
tionalized patients was minimized: 5,137 patients had 656,564 bed-
days, a mean of 127.8 per patient. In our clinical experience,
admissions to the hospital for schizophrenia are usually measured
in weeks, not months. The four-month admission period in the
present data must reflect the impact of two factors that produce
long admissions. The first factor is the chronic schizophrenics who
spend long periods in state hospitals. Second, because readmission
within 12 days is counted as one admission, a series of short
admissions is shown as one admission. In our calculations we took
the mean of the hospital morbidity figures (142.9 days) as the upper
limit of the range and the inpatient register data (127.8 days) as the
lower limit and used the average of these two figures (135.4 days) in
the main calculation.
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Bed-day costs in 1975 dollars were calculated from a recent
study* in which the usual costing procedures were supplemented
by direct observation of time spent with schizophrenic patients.
The first ten days of inpatient care were more expensive (US$74/day) than subsequent days, which were costed at US $61/day.
This study was conducted in a state psychiatric hospital and took no
account of capital costs. We expected psychiatric units in general
hospitals and private psychiatric hospitals to have higher costs, but
as the rebate from third-party insurers was some $75/day in 1976,
the $74 and $61 estimates8 were used for all hospitals.
Long-term mortality data were not available for our cohort.
Instead we used data from the study by Tsuang et al,9 which
involved a conservatively diagnosed cohort of similar age at onset
who had been followed up for 30 years after hospitalization. The
increased mortality risk associated with schizophrenia was
analyzed using a variation of the rank Von Neumann test.10 This
showed that the expected one-year survival probability did not
vary according to the elapsed time in years since diagnosis, and it
could be approximated by subtracting a constant of .0054 for men
and .0066 for women from the survival probability in the normal
Australian life table. The average life expectancy for a schizophre¬
nic patient was obtained by summing the stream of survival
probabilities applicable to patients in each age group.
A review of outcome studies was prepared in connection with
another project.11 The literature did not lend support to the use of
outcome categories more refined than good, median, or poor. A
costing vignette was constructed for the typical case in each of
these outcome categories. A good-outcome case was defined as
having only a single episode requiring 60 days in the hospital, six
subsequent visits to the physician, medication for six months, six
months out of the work force because of illness, and no further
disability. A median-outcome case was defined as requiring close to
the overall average admissions per year, six physician visits per
year, continuous medication for the rest of life, and being in the
work force for only four months each year after the diagnostic
admission. A poor-outcome case was defined as needing about
twice the overall average admissions to the hospital per year, neverbeing able to work, and requiring monthly physician visits and
continuous medication when out of the hospital.
The costs of the prodrome, which all cases were presumed to
have had, were based on the data of Nyman et al,12 and again
costing vignettes for the good, median, and poor cases were
constructed. For the good case, the prodrome was estimated as
three months of loss of work in the year prior to the incident year
and six outpatient visits at which schizophrenia was not the
diagnosis but that were related to the prodrome of schizophrenia.
For the median case, it was estimated as 12 outpatient visits and six
months of loss of work in the year prior to the incident year. For the
poor case, it was estimated as 12 months of loss of work in the yearprior to diagnosis, 24 outpatient visits, and one period of hospi¬
talization of 25 days that was schizophrenia related but that did not
lead to the diagnosis of schizophrenia.
The leaders of Australian psychiatry were surveyed to deter¬
mine the five psychiatrists considered to be most expert in the
treatment of schizophrenia.11 The range of outcome data reviewed
and the costing vignettes were discussed with these five experts,
who were asked to estimate the frequency of the three outcomes.
After reviewing these data they considered that a 30-year outcome
study would reveal that 25% of a cohort would have a good outcome,
40% a median outcome, and 35% a poor outcome as defined by these
categories. The distribution of prodrome severities was considered
to be similar.
Data on weekly earnings and work force participation rates were
obtained from official government statistics.1314 Age- and sex-
specific yearly earnings of normal persons were calculated. A wage
equal to the market value of age-matched female labor was
assumed for housewives, and, to follow the costing model, 90% of
women were costed as employed either in the marketplace or in the
home.
These data were used to perform an incidence-based costing
using the formulas established by Hartunian et al.2 The formulas
used, the steps in the computation, and the results of the sensitiv¬
ity analysis are given elsewhere.3 These data are summarized in
Table 1.
RESULTS
Incidence and Readmlsslon Rates
The average number of first cases in the psychiatric register per
year are shown in Table 2. In all subsequent calculations each of
these figures was increased by 11% to allow for unascertained cases
admitted to unauthorized hospitals.
The life expectancy in schizophrenics and normal persons is
shown in Table 3. The mean life expectancy after diagnosis is 37.22
years for men and 38.62 years for women, some six years shorter
than that for age- and sex-matched normal persons. Given that
each patient can expect an average of 3.52 readmissions in his or
her lifetime, the yearly readmission rate is 0.095 for men and 0.091
for women. Using these rates, the yearly readmission risk for
patients with good outcome is zero, for those with median outcome
was calculated as 0.086 (men) and 0.083 (women), and for those
with poor outcome was calculated as 0.172 (men) and 0.166(women).
Direct Costs
First admissions were costed on the basis of 60 days for the good-
outcome case and 135 days for the other outcomes. All recurrent
admissions have been costed on the basis of an estimated duration
of admission of 135 days. Thus, the cost of an admission (any age or
sex) is $74/day for the first ten days and $61/day for the remaining
days, giving a total cost for the 135-day admission of $8,401. Other
costs in the first year include outpatient visit costs: patients with
good outcome have six, with median outcome six, and with poor
outcome 12. We used the cost of $29.43 as the cost of a 15- to
30-minute visit to a consultant psychiatrist in 1975 and $7.36 as the
estimate of drug costs, giving a total cost of $36.79 per visit.15 An
additional cost in the first year is the annual recurrence cost, which
is estimated by multiplying the risk of recurrence by the cost of a
recurrent admission. The annual follow-up cost is estimated by
adding the outpatient costs to the annual recurrence cost. The cost
for the second and subsequent years (Table 4) are obtained by
adding for each year of expected life the estimated outpatient and
inpatient costs and then discounting the total by the discount rate.
The estimates for the total direct costs are also shown in Table 4.
Table 1.—Data for Estimating the Cost of
Schizophrenia in New South Wales, Australia*
Best Estimate
No. of new cases in year 1,058
Discount rate, % 6
Average length of stay
per admission, days 135
Bed-day costs, $
1st 10 days 74
Subsequent days 61
Mortality deficit
Men -0.0054
Women -0.0066
Likelihood of readmission/year
Men 0.095
Women 0.090
Distribution of prodrome
and outcomes, %
Good 25
Median 40
Poor 35
Employment (participation) rate
Men Actual for 1979
Women 90% of rate for men
*ln 1975 US dollars.
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Forgone Earnings
Because of the reduced life expectancy in schizophrenia (Table
3), even if a schizophrenic patient lost no time from work due to his
or her illness, he or she would experience reduced lifetime earnings
compared with a normal person. More important, earnings are
forgone because of time lost from work.
In the good-outcome group, therefore, the forgone earnings
consisted of six months of loss of earnings in the year of onset plus
the difference between the normal lifetime earnings and the
reduced potential schizophrenic lifetime earnings because of mor¬
tality. In the median-outcome group, the lifetime earnings forgone
are estimated as two thirds of the hypothetical schizophrenic age-
and sex-specific lifetime earnings based on the assumption that
this group averages only four months of work per year for the
remaining lifetime following diagnosis. The poor-outcome group
are assumed not to work following onset of the condition, and their
forgone earnings are estimated to equal the expected lifetime
earnings for the period after diagnosis.
The average forgone earnings per case were calculated. The total
forgone earnings then were the product of the number of new cases
of that outcome in the year and the average forgone earnings per
patient of that age and sex (Table 5).
The direct, indirect, and total costs of the prodrome, calculated
with the conventions specified previously, are shown in Table 6. A
summary of the total costs of schizophrenia obtained by adding the
direct, indirect, and prodrome costs, together with the costs of
myocardial infarction in Australia and the United States, are
shown in Table 7. Data on the costs per case and the cost per head of
population in NSW and the United States are also appended.
Table 2.—Average Number of First Cases of Schizophrenia
in Psychiatric Register per Year, 1974-1977
No. of Patients
Age, yr Male Female
10-14
_27_3.3
15-19_7O0_46.0
20-24_135.3_72.7
25-29_108.7_82.0
30-34_63 _65.7
35-39_487_52.0
40-44_303_36.3
45-49_3U)_37.7
50-54_26_7_41.0
Total 516.3 436.7
COMMENT
Schizophrenia is a costly disease. In NSW it cost $131,333
per case, or $29 for every man, woman, and child residing in
the state. The ratio between indirect and direct costs was
4.64. Acute myocardial infarction in NSW was costed by the
same method.6 In 1979, 13,025 persons had their first heart
attack; thus, the disorder strikes 12 times as many persons
as does schizophrenia, but the per-case cost of schizophre¬
nia is some six times greater. Thus, the total cost of
schizophrenia was found to be half that of myocardial
infarction. These cost comparisons are presented in 1975
US dollars in Table 7, together with data from the study of
Hartunian et al.2 The cost per case of myocardial infarction
in the United States was 1.6 times that in NSW because
both direct and indirect costs in the United States are
higher. It is not unreasonable to expect that the costs of
schizophrenia in the United States would be increased by
similar factors.
There are a number of issues to be discussed. The first is
the stability and validity of the admission diagnosis. To
establish the stability of the diagnoses we obtained two
samples of patients. Of 50 first-admission patients dis¬
charged as schizophrenic, three were admitted with other
diagnoses and therefore may have been lost to the register.
Of 100 random first-admission patients, only one was admit¬
ted as a schizophrenic and subsequently rediagnosed. This
Table 3.—Life Expectancy in the General Population
and Patients With Schizophrenia
Life Expectancy, yr
General Population Schizophrenia
Age, yr Male Female Male Female
10-14_58_4_65J3_49J5_52.4
15-19_53_6_604_45J)_49.1
20-24_49J_55^5_42J5_45.9
25-29_44_4_50V_ 39.0_42.5
30-34_39_7_45JS_35_3_38.9
35-39_35_0_41 _3JL4_35.4
40-44_304_36J3_27JS_31.7
45-49_26 _317_23J}_28.1
50-54 218 27.3 20.3 24.5
Table 4.—Direct Costs of Schizophrenia in New South Wales, Australia*
Age at
Onset, yr
No. of New Cases 1st-yr Costs Costs After 1 st yr Total Direct Costsf
Male Female Male Female Male Female Male Female
10-14 3.0 3.7 24,679 30,826 44,675 54,352 69,353 85,177
15-19 77.7 51.1 646,938 424,580 1,154,188 742,432 1,801,126 1,167,012
20-24 150.2 80.7 1,250,735 670,834 2,204,912 1,160,820 3,455,647 1,831,654
25-29 120.6 91.0 1,004,371 756,963 1,736,807 1,291,475 2,741,178 2,048,438
30-34 70.0 72.9 582,234 606,121 977,806 1,012,775 1,560,040 1,618,897
35-39 54.0 57.7 449,804 479,980 726,256 780,439 1,176,061 1,260,420
40-44 33.7 40.3 280,289 335,418 429,154 526,239 709,443 861,657
45-49 34.4 41.8 286,505 347,706 410,111 521,452 696,616 869,157
50-54 29.6 45.5 246,477 378,527 323,942 535,038 570,419 913,564
All ages 4,772,032 4,030,954 8,007,851 6,625,023 12,779,884 10,655,976
Both sexes 8,802,986 14,632,874 23,435,860
*ln 1975 US dollars.
tRow and column discrepancies are due to rounding.
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Table 5.—Indirect Costs due to Forgone Earnings*
Costs per Case by Outcome
No. of
New Cases
Age at Onset, yr Male Female
Good(25% of Cases)
Median(40% of Cases) Poor(35% of Cases)
Total Costs, NSW,
1975/1976t
Male Female Male Female Male Female Male Female
10-14 3.0 3.7 15,930 15,422 103,670 84,499 147,474 118,985 287,316 294,203
15-19 77.7 51.1 17,796 17,968 125,288 101,325 179,973 144,300 9,134,009 4,876,647
20-24 150.2 80.7 19,391 18,409 137,002 110,292 198,041 158,258 19,372,820 8,398,501
25-29 120.6 91.0 18,936 17,477 136,071 105,310 197,489 151,579 15,474,882 9,060,681
30-34 70.0 72.9 17,410 15,630 127,531 97,365 185,718 140,529 8,417,196 6,707,773
35-39 54.0 57.7 15,288 13,478 114,098 88,972 166,692 128,852 5,823,552 4,851,746
40-44 33.7 40.3 12,948 11,625 97,348 80,020 142,698 116,392 3,100,776 3,051,007
45-49 34.4 41.8 10,380 9,691 78,620 68,638 115,669 100,317 2,564,477 2,717,167
50-54 29.6 45.5 8,482 7,624 57,930 54,839 85,584 80,588 1,635,306 2,369,202
All ages 573 485 65,810,333 42,326,927
Both sexes 1,058 108,137,260
*ln 1975 US dollars.
fNSW represents New South Wales, Australia.
Table 6.—Prodrome: Direct and Indirect Costs*
No. of New Cases Total Direct Costs Total Indirect Costs
Total Prodrome
Costs, NSW, 1975 1976f
Age at Onset, yr Male Female Male Female Male Female Male Female
10-14 3.0 3.7 3,316 4,156 3,316 4,156
15-19 77.7 51.1 87,050 57,193 194,333 170,273 281,382 227,466
20-24 150.2 80.7 168,296 90,377 855,770 414,317 1,024,066 504,694
25-29 120.6 91.0 135,145 101,972 869,744 540,014 1,004,889 641,986
30-34 70.0 72.9 78,345 81,650 550,432 421,635 628,777 503,284
35-39 54.0 57.7 60,520 64,665 432,554 310,077 493,075 374,742
40-44 33.7 40.3 37,710 45,183 265,331 220,228 303,041 265,411
45-49 34.4 41.8 38,551 46,841 251,606 230,778 290,157 277,619
50-54 29.6 45.5 33,162 50,997 215,552 243,194 248,714 294,191
All ages 642,095 543,035 3,635,323 2,550,515 4,277,418 3,093,550
Both sexes 7,370,968
*ln 1975 US dollars.
tNSW represents New South Wales, Australia. Row and column discrepancies are due to rounding.
Table 7.—Costs of Schizophrenia in NSW, Myocardial Infarction in NSW, and
Myocardial Infarction in United States*
Schizophrenia in NSW Myocardial Infarction in NSW
Myocardial Infarction
in US, 1975t
Male Female Male Female Male Female
No. of cases 573 485 8,238 4,787 226,433 74,366
Population 2.4M 2.39M 2.54M 2.54M 104.24M 109.39M
Direct costs $13.42M $11.20M $21.84M S11.46M $1,134.41M $369.45M
Indirect costs $69.45M $44.88M $200.00M $61.40M $7,804.9M $1,455.6M
Indirect/direct cost ratio 5.18 4.01 9.16 5.36 6.88 3.94
Total cost S82.87M S56.08M $221.84M S72.86M $8,939.31 M S1.825.05M
Cost per case $144,625 $115,629 $26,929 $15,221 $39,477 $24,542
Cost per head of population $34.57 $23.44 $81.51 $28.64 $85.76 $16.68
Both sexes
Total cost S138.95M $294.71 M $10,764.37M
Cost per case $131,333 $22,626 $35,785
Cost per head of population $29 $58 $50
*ln 1975 US dollars. NSW represents New South Wales, Australia; M, million.
fData from Hartunian et al.2
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case may have been wrongly included in the register. To
decide the extent to which the diagnoses of the period would
be congruent with DSM-III criteria, we drew a sample of 50
first-admission schizophrenics with a mean age of 25 years.
Forty-nine met the full criteria for symptoms and one
satisfied the criteria on a later admission. In 48 patients,
role deterioration was recorded while in the other two no
mention was made of role performance. Forty-nine were
aged less than 45 years at onset of the symptoms (or
prodrome), and in the remaining case, symptoms began at
51 years of age with no mention of a prodrome. Emphasis on
the prodrome was unusual in the mid-1970s and the notes
seldom made explicit mention of this feature, hence data on
duration of illness plus prodrome were difficult to obtain.
The minimum length of illness, as described in the records,
was greater than six months in 37 cases, between one and
six months in 11 cases, under one month in one case, and
uncertain in the remaining case. If these samples are
representative of the whole material, then the diagnostic
stability and validity of cases in the register were high. In
the further interest of the DSM-III congruence, we in¬
cluded in the costing analysis only patients from the regis¬
ter who had a first admission before age 55 years in the
expectation that, because of the high likelihood that all the
older patients would have shown prodromal symptoms,
virtually all would have had onset of symptoms prior to age
45 years and thus would be consistent with DSM-III.
The second issue is whether the data used for estimating
direct and indirect costs were valid. The direct costs were
obtained from independent sources and the indirect costs
estimated from a categorization of outcome that was con¬
sistent with the literature and believed to represent experi¬
ence in Australia. The sensitivity analysis3 shows the effect
of varying these parameters in a systematic fashion and
underscores the importance of the discount rate, wage
levels, and female employment levels in estimating costs.
The third problem concerns the applicability of these
estimates to other cultures. In 1976, Australia had a fee-for-
service health system with 70% of the population privately
insured, while the aged and indigent were supported by a
federally supported insurance system. Public and private
hospital costs were covered by such health insurance, while
state psychiatric hospital care was paid from a mix of state
and federal funds. Australia is a less affluent country than
the United States, and costs per case are considerably less
than in the United States. Attention to the absolute costs in
this report may therefore be misleading. Attention should
be paid to the comparison with myocardial infarction and to
the comparison between myocardial infarction costs in the
United States and Australia, for the Australian heart
disease study was a replication of the US estimate of the
cost of heart disease by Hartunian et al.2 Using this
comparison ratio (1.6:1) we estimate the 1975 costs of
schizophrenia in the United States to have been approx¬
imately $208,000 per case or $9.6 billion in all, given that the
incidence was the same as in Australia.
This is not the sum total of costs. No account is taken of
the pain and suffering experienced by the patient and his or
her family. Other costs conceivably could be estimated,
such as those due to disruption to the livelihood of other
family members and to action by social agencies. Social
security payments or pensions, although a very real factor
in the long-term outcome of schizophrenia, are not included
in the costing, for there is an economic convention that they
are to be regarded as transfer payments from one part of
society to another and do not represent a true loss of
productivity. In the present study health insurance admin-
istration costs were also omitted.
There have been previous attempts to cost mental illness,
and such estimates have pointed to schizophrenia as a major
contributor to overall costs. Fein16 made one of the earliest
estimates of the costs of mental illness to the US economy.
He produced an estimate based on the treated prevalence of
mental illness. Direct costs were measured by "actual dollar
expenditures on mental illness"16*10' and were obtained by
adding together the expenditures of various branches of
government on mental hospitals and an estimate of the
amount of money spent on private psychiatry. The result
was an aggregate figure that could not be broken down to
see which diagnoses were contributing most to total direct
costs. An analysis by age group showed that the "cost
problem for hospitals lies in the 25-34 age group, "16(pl05)
which is the peak period for the incidence of schizophrenia.
In estimating indirect costs, Fein was able to provide an
analysis by diagnosis. The result was unequivocal: schizo-
phenia was easily the most expensive illness. It accounted
for 368,522 years of lost productivity among men, well
ahead of the next most costly category, alcoholism, which
accounted for 78,081 years of lost productivity.
More recently, an attempt has been made to provide a
prevalence-based costing of schizophrenia. Gunderson and
Mosher17 provided an estimate of the direct and indirect
costs of schizophrenia in the United States in 1975. Direct
costs were estimated by summing the following quantities:(1) the average costs per day in state, general, and private
hospitals multiplied by the number of schizophrenics re¬
ceiving inpatient care in each type of hospital for a year; (2)
the number of outpatient terminations multiplied by the
average cost of each; and (3) the number of halfway-house
residents multiplied by the average annual cost per resi¬
dent. These calculations produced an estimated annual
direct cost of between (US) $2 and $4 billion. Indirect costs
were estimated by multiplying "the degree of work disabil¬
ity by the average number of people possessing it by the
average expectable yearly income."17*9021 These calculations
yielded estimates of between $8.5 and $11.4 billion. When
direct and indirect costs were added together with mis¬
cellaneous expenses, the total cost came to between $11.6
and $19.5 billion. The lowest of these estimates of the cost of
schizophrenia in the United States amounted to 2% of the
gross national product for 1975.18 We estimated the US 1975
cost as $9.6 billion, and, although more conservative as
would be expected with an incidence-based approach, our
estimate affirms the accuracy of the earlier study.
Implications for Cost-Benefit Studies
This type of costing allows one to explore some implica¬
tions for public policy. Given that schizophrenia costs the
community so much, it could be claimed that too little is
being invested in promoting new treatments or in develop¬
ing new lines of research. Given these costing data, cost-
benefit calculations become very simple. For example, a
number of workers18"22 have recently claimed that the out¬
come can be substantially improved and relapse inhibited
by the use of specific social intervention strategies. To
illustrate the utility of this incidence-based costing, we
reviewed these studies and found results on 622 patients
who had received some type of social intervention in addi¬
tion to drugs and who were followed up for an average of 15
months after family intervention began. They were com¬
pared with control patients given drug therapy. Interven¬
tion was reported to reduce readmission by an average of
45%. (The reduction varied from -15% to 100%; the median
was 44%.) These studies did not provide data on return to
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work, but for the purposes of the present example we have
estimated that there was a small (5%) increased chance of
the treated patients reentering the work force. Given these
data we calculated the costs and benefits that would result
from the introduction of family intervention programs for
all new patients with schizophrenia in NSW. The costs of the
treatment were estimated from those described by Cardin
et al28 at $388 (1982) per year, per patient. We made the
assumption, which is likely to overestimate the costs, that
such therapy would have to continue at this intensity for the
life expectancy of the patient. When this cost was converted
to 1975 dollars, discounted at 6% per annum for the life
expectancy period (38 years), and multiplied by the number
of patients (1,058), the total was $4.55 million. On detailed
examination, we found that direct costs could be equated,
for the purposes of this example, with admission cost. The
benefits that derived from a 45% reduction in the second-
and subsequent-year direct costs shown in Table 4 were$6.58 million, and from a 5% reduction in forgone earnings
shown in Table 5, $5.41 million. The potential savings
therefore totaled $11.99 million. Thus, a clear cost advan¬
tage from the adoption of these social intervention
therapies is likely.
One problem with the introduction of such therapies is
that they are "nonproprietary" and hence no money is
customarily expended to advertise or promote them. The
pharmaceutical industry is not philanthropic, yet given the
advent of anew drug of similar effectiveness, it would spend
heavily to promote the new product.24 The potential savings
to third-party insurers and to state and federal treasuries
from the adoption of these new social intervention strate¬
gies are considerable, and yet in Australia there has been no
move to promote the new treatments. In part, this is an
organizational problem within medicine—we have had no
mechanism to promote effective nonproprietary remedies
such as psychotherapy, behavior therapy, lithium carbon¬
ate, and now social interventions in schizophrenia,25 while
we have had very effective means of promoting proprietary
remedies whether they be drugs or appliances. Cost-bene¬
fit analyses based on incidence-based costings of disease
may provide one tool to redress this balance.
Implications for Research
If schizophrenia costs the community half what myocar¬
dial infarction does, then clearly we should be spending
something approaching half the myocardial infarction re¬
search budget on schizophrenia. We surveyed funding agen¬
cies in Australia for research grants with schizophrenia or
myocardial infarction in the key words or titles. In 1982
Australia spent $840,000 on applied research into myocar¬
dial infarction and $4.3 million on heart disease in general,
while only $60,000 was spent on schizophrenia research.
Thus, at best, the funding for schizophrenia was only one-
fourteenth that spent on myocardial infarction. In part this
disparity exists because schizophrenia is not at present a
scientifically fashionable field. Somehow we must develop
strategies to change this and encourage both basic and
applied research into schizophrenia. It is not just a matter
of more money but of enticing new people into the field.
Articles like Garfield's recent review26 are valuable for they
can sensitize scientists in other fields to current issues in
schizophrenia research. Over and above this type of ini¬
tiative, we need some inducement to encourage both basic
and applied scientists to consider the relevance of their
current research to schizophrenia. We cannot guess from
which direction new developments will emerge, so task-
force approaches are not likely to prove effective. One
cannot help but be attracted by Horrobin's suggestion of
substantial prizes as inducements for research.27 After all,
there are two notable examples where this strategy has
solved difficult technical problems: the need for an accurate
chronometer in 1735 and the first man-powered flight in
1980. Clearly some original solution is required, for our
current system of funding research is not producing the
rapid growth in knowledge that might have been expected
to follow Kraepelin and Bleuler's delineation of the disorder
70 years ago.
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